Literature DB >> 29937312

[The influence of anxiety and depression on COPD exacerbations].

M Underner1, A Cuvelier2, G Peiffer3, J Perriot4, N Jaafari5.   

Abstract

INTRODUCTION: Exacerbations are common during the course of chronic obstructive pulmonary disease (COPD) and contribute to its morbidity and mortality. COPD is also associated with high prevalence of anxiety and depression.
OBJECTIVES: A systematic literature review of data on the association between anxiety and/or depression and COPD exacerbations. DOCUMENTARY SOURCES: Medline search, for the 1980-2017 period, with the following keywords: "chronic obstructive pulmonary disease" or "COPD" and "exacerbation" and "anxiety" or "depression"; limits: "title/abstract"; the selected languages were English or French.
RESULTS: Among 152 articles, 77 abstracts have been preselected for a dual reading and 30 studies have been finally selected. The prevalence of anxiety and depression ranged from 6.7 to 58% and 5.5 to 51.5%, respectively. Among the 30 studies included in this review, 19 (63.3%) revealed positive associations between anxiety and/or depression and increased risk for exacerbations, although 11 (36.7%) failed to support such an association. The association between anxiety and/or depression and an increased risk of COPD exacerbations was more frequently observed in studies using an event-based definition (85.7%) than in those using a symptom-based definition (14.3%). The main limitation of this review is the high heterogeneity of the studies included. Another limitation is the low rate of women included in this review (32.6%).
CONCLUSION: Anxiety and/or depression are associated with a greater risk for exacerbations to occur in COPD. However, a high heterogeneity across the published studies makes it difficult to draw any firm conclusions on the amplitude of this increased risk.
Copyright © 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anxiety; Anxiété; Bronchopneumopathie chronique obstructive; COPD exacerbation; Chronic obstructive pulmonary disease; Depression; Dépression; Exacerbation de BPCO

Mesh:

Year:  2018        PMID: 29937312     DOI: 10.1016/j.rmr.2018.04.004

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  5 in total

1.  Effect of high quality nursing and respiratory training on pulmonary function and quality of life in patients with chronic obstructive pulmonary disease.

Authors:  Qiubo Zhang; Sufang Liu; Gang Gu; Lingbo Wu; Zimeng Zhu; Yuhong Mao; Fen Zhang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

2.  Effect of Qigong on self-rating depression and anxiety scale scores of COPD patients: A meta-analysis.

Authors:  Jian-Jun Wu; Ying-Xue Zhang; Wei-Sha Du; Liang-Duo Jiang; Rui-Feng Jin; Hui-Yong Yu; Jin-Min Liu; Mei Han
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  Medication adherence among patients with chronic obstructive pulmonary disease treated in a primary general hospital during the COVID-19 pandemic.

Authors:  Hai-Qin Zhang; Jia-Yuan Lin; Yi Guo; Shuai Pang; Ren Jiang; Qi-Jian Cheng
Journal:  Ann Transl Med       Date:  2020-09

4.  Co-Morbidity Patterns Identified Using Latent Class Analysis of Medications Predict All-Cause Mortality Independent of Other Known Risk Factors: The COPDGene® Study.

Authors:  Yisha Li; Margaret Ragland; Erin Austin; Kendra Young; Katherine Pratte; John E Hokanson; Terri H Beaty; Elizabeth A Regan; Stephen I Rennard; Christina Wern; Michael R Jacobs; Ruth Tal-Singer; Barry J Make; Gregory L Kinney
Journal:  Clin Epidemiol       Date:  2020-10-27       Impact factor: 4.790

5.  A protocol of randomized controlled trial for Modified Xiaoyao Powder in the treatment of chronic obstructive pulmonary disease combined mild to moderate depression.

Authors:  Keling Chen; Keni Zhao; Wujun Wang; Wei Xiao; Jing Xiao; Yang Yang; Yufei Liu; Xiaohong Xie
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.